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1. Abstract 
Dendritic cells (DCs) play an essential role in orchestrating and regulating 
the immune response against many pathogens. In this dissertation, the 
importance of DCs in host defense against the clinical relevant bacterium 
Staphylococcus aureus (S. aureus) was investigated. 
Immunofluorescence live-cell imaging was used to demonstrate the high 
efficiency of DCs to phagocyte S. aureus. Bacterial uptake induced a fast 
maturation of DCs as shown by the up-regulation of the co-stimulatory 
molecules CD40, CD80, CD86, and MHC class II, as well as by the pro-
duction of the inflammatory cytokines IL-6, IL-12, and TNFα. In addition, 
DCs were rapidly mobilized and recruited into infected tissue after intrave-
nous inoculation of mice with S. aureus. CD11c-DTR transgenic mice 
were then used to evaluate the relevance of DCs for host defense against 
S. aureus. These transgenic mice express the diphtheria toxin (DT) recep-
tor on the CD11c promoter region, which allows for selective depletion of 
DCs followings the intraperitoneal administration of DT. In vivo depletion of 
DCs resulted in accelerated mortality and significantly increased bacterial 
loads in the lungs and kidneys of infected mice. Reconstitution of DC-
depleted mice by adoptive transfer of DCs from BALB/c mice returned the 
capacity of these animals to control S. aureus infection. Furthermore, in-
crease in DCs numbers in normal mice resulted in enhanced resistance to 
infection.  
The beneficial effect afforded by DCs was not attributed to a direct contri-
bution to bacterial killing. Interestingly, depletion of DCs resulted in a more 
rapid influx of primary polymorph nuclear neutrophils (PMNs) to the site of 
infection; a significant increase in the local production of CXC chemokines 
and increased survival of S. aureus within the recruited PMNs.  
The results of this study provide compelling evidence that DCs are im-
portant regulators of the host immune response to S. aureus and of benefit 
for the host. These data may be of use in future studies for the develop-
ment of new therapeutic strategies for the treatment of S. aureus infec-
tions.
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2. Introduction 
2.1 Staphylococcus aureus 
2.1.1 Microbial characterization of Staphylococcus aureus  
The species Staphylococcus aureus (S. aureus) is the most prominent of 
the genus Staphylococcus in relation to human diseases [1, 2]. It was orig-
inally discovered by the surgeon Sir Alexander Ogston in pus from surgical 
abscesses in the year 1880 and described as: 
“Micrococcus, which, when limited in its extent and activity, causes acute    
suppurative inflammation (phlegmon), produces, when more extensive 
and intense in its action on the human system, the most virulent forms of        
septicæmia and pyæmia” [3, 4]. 
S. aureus is a gram-positive, non motile, non spore-forming facultative an-
aerobic, catalase and coagulase positive coccus that is able to induce ß-
haemolysis. Traditionally, it was considered to be an extracellular patho-
gen [2, 5], but increasing evidence indicates that S. aureus might be a 
facultative intracellular pathogen [6-10]. Staphylococci appear in grape-like 
clusters. The species name “aureus”, which means “golden” in Latin is due 
to the yellow-golden color of the colonies [11]. The color is imparted by 
carotenoid pigments that supports the bacteria in the prevention of oxidant 
killing by phagocytes [12]. Around 20% of the population is persistently 
and around 30% intermittently colonized by S. aureus in the nose or in the 
axilla region, groin areas, or gastrointestinal tract [13]. 
 
2.1.2 S. aureus virulence factors 
The remarkable success of S. aureus as a pathogen is due to the expres-
sion of a wide array of virulence factors including a capsule as well as sur-
face-exposed and secreted proteins [14-16]. A schematic representation 
of S. aureus virulence factors is depicted in Figure 1. In more detail, coag-
ulase is an extracellular protein that reacts with prothrombin in the blood to 
form a complex called staphylothrombin. The protease activity of this 
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complex converts soluble fibrinogen to fibrin. This results in clotting of the 
blood that might protect the bacterium from phagocytic uptake by immune 
cells [17]. The clumping factor binds serum fibrin/fibrinogen and reduces 
the activity of phagocytic immune cells [18, 19]. Protein A is able to bind 
immunoglobulins through their Fc region thereby hampering Fc receptor-
mediated opsonophagocytosis [20, 21]. Furthermore, protein A can induce 
T cell-independent proliferation and apoptosis of B cells [22]. The elastin-
binding protein mediates adhesion of S. aureus to elastin-rich cell surfaces 
such as lungs, skin, or blood vessels [23], while the collagen-binding [24, 
25] and the fibronectin-binding [24, 25] proteins support adhesion of S. 
aureus to connective tissue and extracellular matrix. Enterotoxin B and 
toxic-shock-syndrome-toxin 1 (TSST-1) are bacterial superantigens that 
bind MHC II complexes on antigen-presenting cells leading to immuno-
suppression [26-28]. The α-toxin is the best-characterized and more po-
tent cytotoxin of S. aureus [29]. It binds to cell surface receptors and lipid 
bilayers on host cells and form pores that eventually cause cell death  
[29-31]. 
 
Figure 1: Schematic representation of S. aureus virulence factors. Surface 
and secreted proteins according to growth phase are shown in panel A. Cross 
sections of cell envelope are shown in panels B and C. Figure taken from Lowy, 
1998 [2]. 
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2.1.3 Adhesion and invasion of S. aureus 
Adherence of S. aureus to the host extracellular matrix is the initial step in 
the infection process and is mediated by bacterial surface adhesins, 
known as MSCRAMMs (microbial surface components recognizing adhe-
sive matrix molecules) [32]. MSCRAMMs bind to extracellular matrix pro-
teins such as fibrinogen (ClfA, ClfB), fibronectin (FnbpA, FnbpB), and col-
lagen (Cna) [33]. Certain MSCRAMMs, such as ClfA and SdrC are found 
in virtually all clinical S. aureus strains, whereas others, such as Cna and 
SdrD, are present only in a subset of strains [34]. In addition to mediate 
the bacterium attachment to the extracellular matrix, certain MSCRAMMs 
are able to mediate the internalization of S. aureus within eukaryotic cells. 
S. aureus is generally thought to be an extracellular pathogen, but it can 
be internalized by a variety of cell types in vitro including fibroblasts, oste-
oblasts, keratinocytes, and endothelial cells [35]. This may be an important 
process in systemic spread of infection, escape from antibiotic pressure 
and evasion of the host immune system [36]. The dynamic process of S. 
aureus attachment and invasion is illustrated in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Attachment and invasion of S. aureus in endothelial cells. 
Figure taken from Schröder et al., 2006 [37]. 
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The schematic representation in Figure 2 shows S. aureus attached to 
α5β1-integrins on the surface of endothelial cells via fibronectin fibrils that 
are bound to the fibronectin-binding protein FnBPA (attachment). The host 
cell integrins are associated with myosin bound tensins, and by contrac-
tion of the myosin, the bacteria are transported towards the cell center 
(transport). The uptake is performed by tensin-mediated actin reorganiza-
tion (actin remodeling).  
 
2.1.4 S. aureus infections 
S. aureus can cause a wide variety of infections including skin and soft-
tissue infections such as folliculitis, impetigo, furuncles, carbuncles, and 
cellulites [2]. If the bacterium is able to enter the bloodstream, it can cause 
live-threatening invasive infections such as bacteremia, infective endocar-
ditis, osteomyelitis, or sepsis [38, 39]. Other infections caused by S. 
aureus include catheter-related infections, joint infections, pulmonary in-
fections, and central nervous system infections [39]. S. aureus is associat-
ed with an increasing number of both community-acquired and hospital-
acquired cases of pneumonia. Recent studies have reported that S. 
aureus comprises more than 25% of community-acquired and more than 
40% of hospital-acquired pneumonia cases [40]. A most severe outcome 
of S. aureus bacteremia is the development of sepsis. Sepsis is described 
as an extensive clinical syndrome that is due to an overwhelming re-
sponse of the immune system to an infection progress, followed by immu-
nosuppression [41, 42]. Whereas the most important mediator of gram 
negative-associated sepsis is the lipopolysaccharide (LPS), in gram-
positive bacteria the cell wall components peptidoglycan and lipoteichoic 
acid play a dominant role. In addition to these components, some strains 
of S. aureus produce diverse exotoxins like TSST-1, which act as super-
antigens and are therefore able to induce T lymphocyte activation followed 
by a massive release of pro-inflammatory cytokines [43]. 
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2.1.5 Antibiotic resistance in S. aureus 
Treatment of S. aureus infections can be difficult since many strains have 
developed resistance to several antibiotics. Penicillin was the first antibi-
otic introduced in the clinic to treat S. aureus infections. The mode of ac-
tion of penicillin consists in the inhibition of peptidoglycan synthesis on the 
bacterial cell wall [44, 45]. Shortly after its introduction, S. aureus strains 
developed resistance against beta-lactam antibiotics by the acquisition of 
the enzyme beta-lactamase that hydrolytically destroys the beta-lactam 
ring [46]. Methicillin, introduced in 1961, was the first of the semisynthetic 
penicillinase-resistant penicillins due to a different steric orientation of the 
beta-lactam ring. Unfortunately, S. aureus rapidly developed resistance 
against methicillin and other semi-synthetic penicillins [47-49]. Resistance 
to methicillin is mediated by the acquisition of the mecA gene, which 
codes for the penicillin-binding protein PBP2a [50]. Methicillin-resistant 
strains of S. aureus are commonly abbreviated as MRSA. In the USA, the 
percentage of MRSA strains rose from 11% to 59.5% between the years 
1998 – 2003 [51]. In Europe, the epidemiology of MRSA varies widely de-
pending on the country, ranging from 0.6% in Sweden to an average of 
41% in Belgium, Greece, Ireland, and the United Kingdom [52]. 
Vancomycin has been the most reliable therapeutic agent against infec-
tions caused by MRSA strains. This glycopeptide antibiotic was introduced 
in the year 1958 for the treatment of gram positive bacterial infections [53]. 
However, in 1996 the first MRSA resistant to vancomycin was isolated 
from a Japanese patient [54, 55]. Subsequent isolation of several 
vancomycin resistant S. aureus (VRSA) strains from different countries 
has confirmed that the emergence of vancomycin resistance in S. aureus 
is a global issue. 
 
2.2 The host immune response to S. aureus 
With the exception of diseases caused by specific toxins, the pathogenicity 
of S. aureus is mediated by a variety of exoenzymes, adhesins, immuno-
modulating proteins, and the presence of cell wall compounds [56]. These 
virulence factors in combination allow the bacterium to infect virtually any 
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host tissue [57]. Recognition of S. aureus components by innate immune 
cells is the first step of host defense. The toll-like receptors (TLRs) consti-
tute a family of receptors, which distinguish pathogen-associated molecu-
lar patterns such as LPS, peptidoglycan, and lipoprotein [44, 58]. Trigger-
ing of TLR signaling after pathogens recognition leads to the activation of 
transcription factors that in turn induce transcription of genes coding for a 
variety of proteins including cytokines and inflammatory mediators [59]. 
This results in massive invasion of immune cells to the site of infection. 
Virulence studies using knockout mice have shown that TLRs play a criti-
cal role in the innate immune response to staphylococcal infections since 
mice deficient in the expression of myeloid differentiation factor MyD88, a 
cytoplasmic adaptor molecule essential for the signaling of IL-1R/TLR fam-
ily, are highly susceptible to this pathogen [60].  
The staphylococcal protein A is a ligand for the TNF-α receptor 1, which is 
largely expressed on the airway epithelium. The interaction between pro-
tein A and the TNF- -receptor 1 leads to an inflammatory response on 
epithelial cells and the recruitment of primary polymorph nuclear neutro-
phils (PMNs) [61].  
An effective immune response against S. aureus involves PMN recruit-
ment, which are required for bacterial clearance, and abscess formation 
[62-64]. The importance of PMNs in host defense against S. aureus infec-
tion has been demonstrated by recurrent S. aureus infections in patients 
with chronic granulomatous disease, who have a defect in the NADPH 
oxidase and respiratory burst [65]. The resulting substantial invasion of 
PMNs to the site of S. aureus infection is accompanied by central liquefac-
tion necrosis and formation of peripheral fibrin walls in an effort to prevent 
microbial spread [66]. These structures are known as abscesses and they 
generally have a defined fibrinous wall surrounding a purulent focus of 
PMNs and bacteria. 
The early events of the innate immune response culminate in the activa-
tion of the adaptive immune system, during which T and B cells capable of 
specific antigen recognition are generated.  
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2.3 Dendritic cells 
2.3.1 Origin and subdivision of dendritic cells 
Dendritic cells (DCs), discovered by Ralph M. Steinmann in the year 1973, 
represent a special type of leukocytes responsible for activation and con-
trol of both innate and adaptive immune responses [67]. In general, they 
develop in the bone marrow from myeloid precursors that also produce 
monocytes (see schematic representation in Figure 3). DCs are especially 
distributed in tissues that interface the external environment, such as the 
skin, the gut, and the lungs, where they can perform a sentinel function for 
incoming pathogens, and have the capacity to recruit and activate cells of 
the innate immune system [68-70]. After recognition of pathogens, DCs 
undergo a maturation process that leads to their migration to the T cells 
area of lymph nodes where antigen specific cells of the adaptive immune 
response can be primed. DCs are the only cell type capable of initiating 
adaptive immune responses by activating naïve T lymphocytes. Therefore, 
DCs serve as a major link between the innate and the adaptive immune 
response. 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic representation of the origin and differentiation of  
immune cells. Taken from Todar et al., 2011 [71]. 
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2.3.2 Maturation of DCs 
DCs reside in an immature state in several tissues such as skin, pharynx, 
esophagus, or genitals. Furthermore, they are found in mucous mem-
branes like respiratory and gastrointestinal tracts [72, 73]. Immature DCs 
have a radiating shape with their extensions (“dendrits”) outstretched 
through the tight junctions of tissue epithelia cells, which increases their 
ability to catch antigens [74]. After recognition of pathogens through sur-
face-exposed receptors, DCs increase their expression of the chemokine 
receptor CCR7, which enables them to migrate from the site of infection 
through the afferent lymphatic vessels to the T cell area of the draining 
secondary lymphatic organs (lymph nodes, Peyer-Plaques in the gut, ton-
sils, spleen, and appendix) [75, 76]. During migration, DCs undergo a 
maturation program that results in the up-regulation of co-stimulatory mo-
lecules such as CD40, CD80, and CD86, translocation of their MHC class 
II to the cell surface and secretion of inflammatory cytokines (see sche-
matic representation in Figure 4) [77]. Furthermore, the morphology of the 
DCs also changes with maturation. These changes involve reduction of 
dendrits and development of membrane excrescences. The phagocytic 
capacity of DCs is also lost during the maturation process [44].  
 
 
 
 
 
 
 
 
 
Figure 4: Schematic representation of maturation and migration of dendritic 
cells. Taken from [78], modified. 
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2.3.3 Activation of T lymphocytes  
After reaching a lymphatic organ, DCs express a high amount of co-
stimulatory molecules to activate the different types of T cells. By presen-
ting the antigen via the MHC class I or II complexes and the interaction 
between their B7 molecules with the CD28 receptor on the T cells, the T 
cells become activated and leave the lymphatic organ via the efferent lym-
phatic vessels (see Figure 4 and Figure 5) [44]. 
 
 
 
 
 
 
 
 
 
 
2.3.4 DC subtypes 
Different subtypes of DCs have been described according to the surface 
expression of specific markers and tissue distribution [80, 81]. In mice, 
immature conventional DCs are characterized by the expression of 
CD11c, low levels of the co-stimulatory molecules CD80 and CD86, and 
low levels of MHC class II. Interestingly, DCs can also express the T cell 
markers CD4 and CD8 as well as CD11b. The CD8- DCs reside mostly in 
the marginal zone of the lymph nodes while the CD8+ are mainly located in 
the T cell area [81]. Another CD4- CD8- CD11b+ DC population also ex-
pressing moderate levels of the scavenger receptor CD205 has been iden-
tified in all lymph nodes [82]. Finally, DCs in the skin, also known as  
Figure 5: Activation of T lymphocytes by DCs. Taken from Gilboa et al., 
2004 [79]. 
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Langerhans cells, express high levels of Langerin [83].  
In humans, DC subtypes are less characterized. Human DCs do not ex-
press CD8 and, in spleen and tonsils, DCs are positive for CD11b, CD11c, 
and CD4 [81]. 
 
2.3.5 DCs and their role in disease  
Due to their excellent ability to present antigens and thereby activate and 
orchestrate the adaptive immune response, DCs play a pivotal role in the 
host defense against pathogens [77]. In this regard, several studies have 
demonstrated that DCs are required for the survival of mice suffering of 
polymicrobial sepsis [84]. Decreased counts of circulating DCs have been 
reported to correlate with disease severity and predicting a fatal outcome 
in patients affected by the septic shock syndrome [85]. Furthermore, trans-
fer of bone-marrow derived DCs into the lungs of postseptic mice reversed 
immunosuppression and conferred protection against Aspergillus infection 
[86]. The importance of DCs has also been proved in non-septic situa-
tions. For example, DCs are an important inducer of T cell responses dur-
ing Cryptococcus neoformans infections [87] and contribute to the host 
defense against Streptococcus pyogenes [88, 89]. Due to the importance 
of DCs for host defense, certain pathogens have developed mechanisms 
to avoid or even to use the DCs for their own benefit. Thus, DCs infected 
with the measles virus undergo maturation but are unable to induce T cell 
activation and show a high apoptosis rate [90, 91]. However, apoptotic 
measles virus-infected DCs are strong inducers of maturation of uninfect-
ed DCs, what may finally contribute to viral clearance [91]. By replicating 
and surviving within the DCs, Mycobacteria and Salmonella sp. can use 
this eukaryotic cell to disseminate within the host [92-95]. 
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2.3.5 Pathogens strategies to evade DCs 
As the DCs play a central role in the regulation of the immune response, 
many pathogens have developed strategies to prevent DC recognition. 
Salmonella enterica serovar Typhi is a motile bacterium that causes ty-
phoid fever in humans. Their flagellin subunit FliC is an attractive target for 
DCs [96]. It has been shown, that the bacteria dramatically reduce the 
production of FliC as soon as they invaded into the gut cells, as motility is 
no longer required [97]. Therefore, by directing the DCs to induce a T cell 
response against an antigen that is no longer present, Salmonella evades 
the host immune response. Yersinia enterocolitica shows a more direct 
strategy to evade DCs. During infection, the bacteria are able to inject ef-
fector proteins like Yersinia outer proteins (Yops) into the host cells, which 
inhibits antigen presentation by the DCs [98]. Furthermore, Yops proteins 
induce DC apoptosis, and therefore hindering the appropriate stimulation 
of T cells due to the reduced number of DCs [99, 100]. Other pathogens 
such as Helicobacter pylori are able to inhibit the cytokine release of DCs 
by secreting a non-proteinaceous factor and thereby regulating the im-
mune response to its favor [101]. Streptococcus pneumoniae produces 
haemolytic pneumolysin that inhibits the DC maturation, the induction of 
proinflammatory cytokines, and the activation of the inflammasome. If the 
bacteria are taken up by DCs, the intracellular production of pneumolysin 
induces caspase-dependent apoptosis [102]. In summary, the strategies 
developed by different pathogens to evade DCs are based upon their in-
terference with the generation and survival of DCs, the antigen-presenting 
mechanisms, or the interference with T cell activation. 
Aim of the work 
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3. Aim of the work 
In the last decades, S. aureus has been recognized as one of the most 
important leading cause of hospital- and community-acquired infections 
worldwide. As the management of S. aureus infections is a growing clinical 
challenge due to the widespread presence of multidrug-resistant S. aureus 
strains, new therapeutic options are therefore needed for the treatment of 
these infections in a more efficient way. This clinical challenge under-
scores the importance of a better understanding of the pathogenesis and 
cellular mechanisms underlying S. aureus infections. As DCs play a cru-
cial role in protecting the host against pathogens, the aim of the current 
study was to investigate the role of DCs in the complex process of  
S. aureus invasive infection. For this purpose the interactions between  
S. aureus and DCs has been examined using in vitro as well as in vivo 
experimental systems. Live-cell imaging and immunofluorescence tech-
niques have been applied to visualize the phagocytic process of S. aureus 
by DCs. In addition, CD11c-DTR transgenic mice, which allow the selec-
tive depletion of DCs in vivo, have been used to evaluate the relevance of 
DCs for the host defense against S. aureus. 
Material and Methods 
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4. Material and Methods 
  
4.1 Bacterial strains 
The S. aureus strain SH1000 was used in this study. SH1000 was devel-
oped in the year 2002 as a single-copy rsbU gene-complemented deriva-
tive of the wild-type strain 8325-4 [103]. rsbU encodes a positive regulator 
for sigma factor b activity, that is responsible for a general stress response 
[103]. Bacteria were grown to the Mid-Log phase at 37 ºC with shaking 
(150 rpm) in brain heart infusion (BHI)-medium, collected by centrifugation 
for 10 min at 4000 rpm, washed twice with sterile PBS and adjusted to 5 x 
108 CFU/ml. For the inoculum preparation, the bacterial suspension was 
diluted with PBS to the required concentration and the number of viable 
bacteria was determined after serial diluting and plating onto agar contain-
ing 5% of sheep blood (Invitrogen, Karlsruhe, Germany). For live-cell im-
aging, a GFP-expressing SH1000 strain was used [104]. Bacteria were 
grown to the Mid-Log phase at 37°C with shaking (150 rpm) in brain heart 
infusion (BHI)-medium supplemented with 30 µg/ml of Chloramphenicol, 
collected by centrifugation for 10 min at 4000 rpm, washed twice with ster-
ile PBS and adjusted to 5 x 108 CFU/ml. To generate heat-killed  
S. aureus, 109 bacteria were resuspended in 2 ml of PBS and incubated in 
a water bath for 2 h at 95°C. 
 
4.2 Mice 
BALB/c mice were purchased from Harlan-Winkelmann (Borchen, Germa-
ny), B6.FVB-Tg [Itgax-DTR/GFP] 57Lan/J transgenic mice [105] (referred 
in this study as CD11c-DTR) were obtained from Steffen Jung (The 
Weizmann Institute of Science, Rehovot, Israel) and backcrossed against 
a BALB/c background. These mice express a human diphtheria toxin (DT) 
receptor in the promoter region of CD11c. Mice harboring this transgene 
are transiently depleted of CD11c+ populations upon intraperitoneal injec-
tion of diphtheria toxin (DT) (see Figure 6). DC depletion persists for ap-
proximately 2 days after which the cell population gradually recovers. For 
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systemic depletion of DCs, CD11c-DTR transgenic mice were injected 
intraperiotoneally (i.p.) with 4 ng/g body weight of DT (Sigma, 
Deisenhofen, Germany) in PBS 24 h prior to infection. CD11c-DTR inject-
ed i.p. with PBS were used as control. Ovalbumin specific mice B6.Cg-Tg 
(TcraTcrb) 425Cbn/J (referred in this study as OT-II) were purchased from 
Jackson Laboratory (Maine, USA). These mice express the mouse alpha-
chain and beta-chain T cell receptor that pairs with the CD4 co-receptor. 
The T cell hybridoma clone is CD4+, MHC class II-restricted, and is specif-
ic for the ovalbumin residue 323-339 peptides in the context of the MHC 
class II I-A2 molecule [106]. 
Mice were housed in a specific pathogen-free animal facility at the Helm-
holtz Centre for Infection Research. All experiments were approved by the 
ethical board Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit, Oldenburg in Germany, reference number 
33.11.42502-04-024/08. 
 
Figure 6: Depletion of CD11c positive cells in CD11c-DTR mice.  
Figure taken from Bennett et al., 2007 [107]. 
 
Material and Methods 
 
16 
 
4.3 S. aureus infection model 
Mice were inoculated with 4 x 107 CFU of S. aureus in 150 µl of PBS via a 
lateral tail vein. For determination of bacterial loads in organs, infected 
mice were killed by CO2 asphyxiation at different times of infection and the 
amount of bacteria was determined by preparing organ homogenates in 5 
ml of PBS and plating 6-fold serial dilutions on blood agar (Invitrogen). 
Colonies were counted after incubation for 24 h at 37°C. For collection of 
serum, blood was collected at time of sacrifice, centrifuged at 4000 rpm for 
10 min, and frozen at -80°C until use for further analysis. 
 
4.4 Assessment of pathology 
Lungs, kidneys, livers, and hearts were isolated from S. aureus-infected 
DCs-depleted and non-depleted CD11c-DTR mice at 24 h after bacterial 
inoculation, fixed in 10% neutral formalin, processed and embedded in 
paraffin. Four- to five-micrometer sections were prepared and stained with 
hematoxylin and eosin (H&E). The slides were examined by a pathologist 
who was blinded to the study groups. Histopathological lesions were grad-
ed for severity on a scale of 0 to 3. The scores were as follows: 0, non-
pathological signs; 1, Multifocal PMNic interstitial pneumonia, focal puru-
lent necrotizing myocarditis, or focal nephritis; 2, focal purulent abscess 
myocarditis, multifocal necrotizing hepatitis, focal purulent epicarditis, focal 
PMNic myocarditis; and 3, multifocal purulent necrotizing  
hepatitits. 
 
4.5 Isolation of DCs from lungs and spleen 
Spleens were meshed through a cell strainer and transformed in a single 
cell suspension. Lungs were minced with a scalpel and enzymatically di-
gested with collagenase F and DNAse. Cell suspensions were incubated 
at 37°C for 30 min and reactions were stopped with 10 mM EDTA solution 
and red blood cells lysed after treatment with ammonium chloride. The 
percentage of CD11c/CD11b+ DCs was assessed by flow cytometry. The 
absolute numbers of DCs was calculated by multiplying the total cell 
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counts by the percentage of CD11c/CD11b+ cells. In some experiments, 
DCs were purified using anti-CD11c magnetic beads and positive selec-
tion MS columns (Miltenyi Biotec, Bergisch Gladbach, Germany). For this 
purpose, cells were resuspended in 400 µl of RPMI without supplements 
and 100 µl of CD11c micro beads (Miltenyi Biotec) were added to the cell 
suspension. After gently mixing and incubation for 15 min at 4°C, 2 ml of 
media was added and cells were centrifuged for 10 min at 1200 rpm. Dur-
ing this time, MS columns were placed in the magnetic field of a MACS 
separator and rinsed with 500 µl of medium. After centrifugation, superna-
tant was thoroughly removed and cells resuspended in 500 µl of medium. 
The cell suspension was applied to the MS columns and the flow-through 
discarded. Columns were washed three times with medium and flushed 
with 500 µl media to collect the retained cell population. The purity of the 
positive fraction was generally >90% as confirmed by CD11c staining and 
flow cytometry analysis. Purified splenic DCs were in vitro stimulated with 
107 heat-killed S. aureus organisms or with 1 µM CpG for 16 h. The su-
pernatant was used to determine the concentrations of  
cytokines. 
 
4.6 Generation of bone marrow-derived DCs 
Bone marrow cells were flushed from murine femurs and tibias. Progenitor 
cells (106/ml) were resuspended in RPMI 1640 containing 5% FCS, 10 
ng/ml of recombinant mouse GM-CSF (granulocyte-macrophage colony-
stimulating factor), and 2 ng/ml IL-4 (R&D Systems, Minneapolis, USA) 
and cultured for 6 days at 37°C in 5% CO2. On days 2 and 4, DCs were 
gently washed and fed with fresh medium and supplementary factors. On 
day 6, the DC fraction was enriched using an OptiPrepTM (Axis-Shield, 
Oslo, Norway) gradient. Purified DCs were collected from the gradient in-
terface and used for infection experiments. The purity of the resulting cell 
population consisted of >80% of DCs as determined by flow cytometry 
analysis using anti-mouse CD11c antibody (Becton Dickinson, San Jose, 
California, USA) and a FACSCaliburTM flow cytometer (Becton Dickin-
son). 
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4.7 Adoptive Transfer of DCs 
Bone marrow-derived DCs from BALB/c mice were differentiated as de-
scribed above and 106 immature or LPS-matured DCs were intravenously 
(i.v.) inoculated into S. aureus-infected BALB/c or DC-depleted CD11c-
DTR mice at 16 h of infection. For DCs tracking experiments, DCs were 
labeled with 5(6)-Carboxyfluorescein diacetate N-succinimidyl ester 
(CFSE) before adoptive transfer. For this purpose, up to 2x107 DCs were 
incubated with 1 µM CSFE (Sigma) in 1ml PBS for 15 min at room tem-
perature in the dark. The reaction was stopped by adding an equal amount 
of FCS. Labeled DCs were collected by centrifugation, washed twice with 
PBS and used for adoptive transfer experiments. 
 
4.8 Collection of primary polymorph nuclear neutrophils 
BALB/c mice were injected intraperitoneally with 1 mg of carrageenan 4 
and 2 days prior experiment to deplete macrophages and to enrich the 
primary polymorph nuclear neutrophils (PMNs). Mice were euthanized and 
the abdominal cavity was flushed three times with 5 ml RPMI 1640 to col-
lect the PMNs. Cells were centrifuged and directly used for experiments. 
 
4.9 Partial depletion of PMNs in vivo 
To induce a partial depletion of PMNs in vivo, mice were injected intrave-
nously with 20 µg of anti-RB6 antibodies 24 h prior infection. This treat-
ment results in the depletion of about 30% of PMNs as determined by flow 
cytometry.  
                                                 
4.10 Cytokine determination 
Cytokine levels were determined in serum or lung homogenate by ELISA 
(BD Pharmingen, San Diego, CA, USA), using matched antibody pairs and 
recombinant cytokines as standards. 96-well flat-bottom microtitre plates 
were coated overnight at 4°C with 100 µl/well of the corresponding primary 
antibody diluted in coating buffer (0.05 M carbonate buffer, pH 9.6). The 
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coated plates were washed six times with washing solution (0.1% Tween 
20/PBS) using an ELISA washer. After the protein solution was removed, 
plates were blocked with 200 µl per well of 10% FCS in PBS for 1 h at 
37°C. The blocking solution was aspirated and serially diluted (1:2) serum 
samples or undiluted lung homogenates were added (100 µl/well) and in-
cubated overnight at 4°C. After six washes with 0.1% Tween 20/PBS, 
secondary biotinylated antibodies were added and plates were further in-
cubated for 2 h at 37°C. After several washing steps, 100 µl of HRP-
conjugated streptavidin diluted 1:1000 in PBS supplemented with 10% 
FCS was added and plates were incubated for 30 min at room tempera-
ture. Plates were then washed 6 times and reactions were developed us-
ing 100 µl/well of Tetramethylbenzidine (TMB) solution. After appropriate 
incubation times, the reaction was stopped with 50 µl/ well of 2N H2SO4 
solution and the absorbance at 450 nm with wavelength correction at 570 
nm was determined using a Tecan ELISA Reader.   
 
4.11 Flow cytometry 
Cells were incubated with purified rat anti–mouse CD16/CD32 antibodies 
(Pharmingen) for 5 min to block Fc receptors and then stained with fluo-
rescent antibodies against CD11c, CD11b, Gr-1, CD40, CD80, CD86, or 
MHC Class II for 30 min at 4°C. Labeled cells were analyzed by flow 
cytometry in a FACSCaliburTM (Becton Dickinson).  
 
4.12 S. aureus infection of DCs 
Bone marrow-derived DCs were plated in 48-well plates at a density of 5 x 
106/ml and infected with S. aureus at a multiplicity of infection (MOI) of 2 
bacteria per DC. Infected DCs were incubated for 2 h in antibiotic-free 
medium, washed twice with PBS to remove unbound bacteria and further 
incubated in Dulbecco’s modified Eagle medium (DMEM) supplemented 
with 10% FCS and 100 µg/ml of Gentamicin. DCs were collected by cen-
trifugation at the indicated times after infection, washed with PBS and 
stained with antibodies for flow cytometry analysis. 
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4.13 Live cell imaging 
For live-cell imaging, 106 DCs were seeded on 35-mm glass-bottom dish-
es (MatTek Corporation, USA) in DMEM 10% FCS, washed with PBS and 
subsequently maintained in imaging medium (DMEM without phenol red, 
10% FCS, pH 7.4, 2 mM L-Glutamine). DCs were infected with GFP-
expressing S. aureus at a MOI of 1 bacterium per DC. In some experi-
ments, a solution of Lysotracker (Invitrogen, Germany) 1:20000 in DMEM 
imaging medium was added to label the DC acidic compartments. Imaging 
was started after 10 min of incubation using a Leica SP5 confocal micro-
scope (Leica Microsystems, Germany) with AOBS and AOTF and 
equipped with environment control chamber (EMBLEM, Germany). During 
live imaging, single focal plane was monitored in time (xyt scanning mode) 
using 63x/1.4 HCX-PLAPO oil objective, Argon laser (488 nm) and DPSS 
laser (561 nm), scanner frequency 400 Hz; line averaging 4.  
 
4.14 Image analysis 
Processing of the stacks and analysis of the fluorescence intensity was 
performed using the ImageJ 1.38r software (Wayne Rasband, NIH USA). 
All time-lapse series were acquired in xyt scanning mode at a rate of 1 
frame every 20 seconds.  
  
4.15 Intracellular bacterial viability assay 
To determine the amount of viable S. aureus within PMNs, Gr-1+ cells 
were purified from the lungs of infected mice using magnetic beads 
(Miltenyi Biotec), treated with lysostaphin (5 µg/ml) for 15 min to eliminate 
extracellular bacteria and extensively washed to eliminate antibiotic traces. 
PMNs were collected by centrifugation, the cell pellet disrupted after 
treatment with dH2O, and the amount of viable intracellular bacteria de-
termined after serial plating onto blood agar.  
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4.16 Antigen-presentation assay 
DCs were isolated from OT-II mice and differentiated as described in sec-
tion 4.6. After purification, DCs (105/well) were infected with S. aureus or 
left uninfected. Some cells were furthermore co-incubated with 1mg/ml 
ovalbumin peptide. After 1 h, cells were treated with 5 µg/ml Lysostaphin 
for 15 min to eliminate non-phagocytosed bacteria. After washing, cells 
were resuspended in fresh media containing 100 µg/ml Gentamicin and 
further incubated for 6 h. DC were then harvested and seeded into a 96-
well cell culture plate (105/well). Purified CD4+ T cells isolated from spleen 
and lymph nodes of OT-II mice were added (5 x 105/well) and the cultures 
were incubated for 3 days at 37°C, 5% CO2. For isolation and purification 
of CD4+ T cells, spleen and lymph nodes were transformed in a single cell 
suspension and incubated with anti-CD4-PE antibodies (dilution 1:100) for 
15 min at 4°C. After washing, anti-PE-magnetic beads and labeled cells 
were isolated following the procedure described in section 4.5. After 3 
days of culture, 50 µl of fresh media supplemented with 1 µC [methyl-
3H]Thymidine was added and cells were incubated for further 18 h. Cells 
were harvested on glass fibre filters by using the Inotech cell harvester. 
Results were expressed as the arithmetic mean of [methyl-3H]Thymidine 
uptake in counts per minute (cpm). 
 
4.17 Statistical analysis 
Data were analyzed using GraphPad Prism 4.0 (GraphPad software). Un-
less otherwise specified, all data are presented as mean standard devi-
ation (± SD). Comparison between groups was made by use of two-tailed 
t-test. Comparison of survival time curves was performed by use of  
Logrank test. P values <0.05 were considered as significant. 
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5. Results 
5.1 Phagocytic uptake of S. aureus by DCs 
DCs are generally present in all peripheral tissues and accumulate at the 
sites of pathogen entry where they can efficiently phagocyte the invading 
pathogens. DCs could be one of the first cell populations interacting with 
S. aureus after bacterial invasion. The capacity of bone marrow-derived 
murine DCs to uptake S. aureus was investigated by immunofluorescence 
live-cell imaging. DCs were stained red with lysotracker, which stains acid-
ic cellular compartments, and then incubated with GFP-expressing S. 
aureus at a MOI of 1:1. Stills of a representative movie (Video S1, see ap-
pendix I. Videos) are shown in Figure 7. DCs began to internalize S. 
aureus 30 min after co-incubation (Figure 7A, white arrow) and bacterial 
phagocytosis continued unabated (Figure 7B-D, white arrow).  
 
Figure 7: Phagocytic uptake of S. aureus by DCs. Stills from a representa-
tive movie (Video S1) showing phagocytosis of S. aureus by a DC (indicated by 
the white arrow). Bacteria are labeled green (GFP) and the DCs are labeled red 
with lysotracker. 
A 
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After 1 h of infection, a large proportion of the internalized bacteria appear 
in yellow indicating co-localization within acidic phagocytic vacuoles. The 
red and green fluorescence associated with DCs were then quantified us-
ing ImageJ software analysis, which plot the mean fluorescence of repre-
sentative cells in consecutive frames obtained from a live-cell imaging vid-
eo. Representative frames at time 0 and 64 minutes (min) of live imaging 
are displayed in Figure 8A. As shown in Figure 8B, fluorescence associat-
ed with S. aureus significantly increased in sequential frames confirming 
the continuous bacterial uptake by the DCs. Furthermore, the intensity of 
red fluorescence (lysotracker) also increased in a chronological manner 
indicating a progressive acidification of the phagosomes within the DCs 
(Figure 8C).       
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Phagosome acidification in S. aureus-infected DCs. (A) Repre-
sentative frames at time 0 (upper panels) and 64 (lower panels) min of a live-cell 
video showing lysotracker (red), S. aureus (green) and the overlaid image. Fluo-
rescence profile of GFP (B) and lysotracker (C) were analyzed frame by frame 
using ImageJ software.      
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5.2 S. aureus induces maturation of DCs 
Internalization of pathogens can subsequently trigger DC maturation and 
migration from peripheral tissues to lymphoid organs. The process of DC 
maturation, in general, involves a redistribution of MHC Class II from intra-
cellular endocytic compartments to the DC surface, an increase in the sur-
face expression of co-stimulatory molecules as well as secretion of cyto-
kines. Therefore, the ability of S. aureus to induce maturation of DCs was 
determined by measuring the up-regulation of the surface maturation 
markers CD40, CD80, CD86, and MHC class II at 6 h after bacterial infec-
tion. To this end, murine bone marrow-derived DCs were incubated with S. 
aureus for 2 h, extracellular bacteria killed by addition of Gentamicin, and 
DCs were further incubated for 6 h. Uninfected DCs were used as nega-
tive control and DCs stimulated with 2 µg/ml of LPS were used as positive 
control. After 6 h of culture, DCs were labeled with FITC-conjugated mon-
oclonal antibodies to CD40, CD80, CD86, or MHC class II molecules and 
PE-conjugated antibodies to CD11c, and analyzed by flow cytometry. The 
CD11c+ cell population was gated and analyzed for the expression of 
CD40, CD80, CD86, and MHC class II expression. A significant increase 
in the mean fluorescence intensity (MFI) of the different maturation mark-
ers was detected in S. aureus-infected DCs when compared with DCs cul-
tured with medium alone (CTR) (Figure 9A). The average level of matura-
tion markers induced by S. aureus was significantly greater than that in-
duced by LPS after 6 h of stimulation (Figure 9A). In addition, the capacity 
of S. aureus to induce IL-6, IL-12, and TNF-  secretion by DCs was also 
evaluated. For this purpose, the levels of these cytokines were determined 
in the culture supernatant of S. aureus-infected DCs by ELISA. S. aureus 
was found to induce the release of high levels of all these pro-
inflammatory cytokines with the mean values comparable to those induced 
by LPS (Figure 9B). 
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5.3 The mouse model of S. aureus infection 
A murine model of S. aureus bacteremia was then used to determine the 
relevance of DCs for host response against S. aureus. In this infection 
model, BALB/c mice were intravenously inoculated with 4 x 107 CFU of S. 
aureus and the course of infection was monitored by determination of 
weight loss, survival, and bacterial burdens in systemic organs at progres-
sive times after bacterial inoculation. Shortly after infection, all mice dis-
played overt clinical signs of morbidity as determined by a decrease in 
their physical activity, a tendency to huddle, piloerection, and gradual 
weight loss (Figure 10A). Infected mice showed a progressive mortality 
starting at day 2 post-inoculation, with 100% mortality by day 4 of infection 
(Figure 10B) and progressive bacterial growth in kidneys, liver and lungs 
(Figure 10C). In addition, serum levels of IL-6, an early marker of gram-
positive sepsis [108], increased progressively in S. aureus-infected mice 
(Figure 10D). Therefore, the inability of BALB/c mice to clear S. aureus 
infection results in an overwhelming systemic inflammatory response that 
culminates in the development of sepsis and death. 
Figure 9: S. aureus induces maturation of DCs. (A) Mean fluorescence inten-
sity (MFI) of CD40, CD80, CD86, or MHC class II molecules on DCs left untreat-
ed (white bars), stimulated with LPS (hatched bars) or infected with S. aureus 
(black bars) determined by flow cytometry analysis. (B) Levels of IL-6, IL-12 and 
TNF-  determined in the culture supernatant by ELISA. Each bar represents the 
mean ± SD of triplicates from three independent experiments. *, p < 0.05; **, p < 
0.01; ***, p < 0.001. 
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5.4 DCs are recruited into the organs of S. aureus-infected mice 
As depletion of DCs in secondary lymphoid organs has been reported at 
the early phase of polymicrobial sepsis in mice [109, 110], the number of 
DCs in the spleen of S. aureus-infected mice was determined at 24h and 
48 h post bacterial inoculation by flow cytometry analysis. In contrast to 
the reduction of DCs observed in the spleen of mice during polymicrobial 
sepsis, the number of DCs (CD11chigh/CD11bhigh) increased significantly in 
the spleen of S. aureus septic animals (Figure 11A). Recruitment of DCs 
also took place in peripheral organs such as in the lungs (Figure 11B). 
 
 
 
Figure 10: The course of S. aureus infection in BALB/c mice. Body weight 
monitoring (A), survival curves (B), bacterial loads in systemic organs (C) and 
serum levels of IL-6 (D) in BALB/c mice after intravenous infection with 4 x 107 
CFU of S. aureus. **, p < 0.01; ***, p < 0.001. 
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Figure 11: DCs are recruited into the spleen and lungs of S. aureus-infected 
mice. BALB/c mice were infected with 4 x 107 CFU of S. aureus and the amount 
of DCs determined in the spleen (A) and lungs (B) at 24 h and 48 h of infection. 
Each bar represents the mean ± SD of 5 mice per time point. *, p < 0.05; **, p < 
0.01. 
 
The functional capacity of the recruited DCs was then determined by iso-
lating DCs from the organs of infected mice and re-stimulating them  
in vitro for 16 h with 107 cells of heat-killed S. aureus. The production of IL-
12, TNF-α, and IL-6 was measured in the culture supernatant of the re-
stimulated DCs by ELISA. As shown in Figure 12, the DCs isolated from 
infected mice produced significantly higher levels of IL-12 (Figure 12A), 
TNF-α (Figure 12B) and IL-6 (Figure 12C) than those isolated from unin-
fected animals. Similar results were obtained after re-stimulating the iso-
lated DCs with the TLR-9 ligand CpG (data not shown). These results in-
dicate that DCs did not lose their capacity to produce cytokines in  
S. aureus-infected mice and that they were in a more advanced state of 
maturation than DCs isolated from uninfected animals. 
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5.5 Depletion of DCs exacerbates the severity of S. aureus  
   infection 
To determine the relevance of the recruited DCs for host defense against 
S. aureus infection, CD11c-DTR mice were used to selectively deplete 
DCs. As described in the Materials and Methods section, these transgenic 
mice express the diphtheria toxin (DT) receptor on the CD11c promoter 
region, which allows for selective depletion of DCs following the admin-
istration of DT. It was observed that CD11c-DTR mice depleted of DCs 
exhibited significant reduced survival time (Figure 13A) and greater num-
bers of bacteria in the organs (Figure 13B) than non-depleted animals. In 
correlation with the accelerated mortality, DC-depleted mice exhibited 
higher pathology scores than non-depleted animals (Figure 13C). To ex-
clude a potential effect of the DT treatment per se on the course of infec-
tion, BALB/c mice were treated with DT accordingly to the protocol used 
for the CD11c-DTR mice and the bacterial burden in systemic organs was 
determined. No differences were observed in the amount of bacteria be-
tween DT-treated and untreated BALB/c mice (Figure 13D). 
 
 
Figure 12: Cytokines released by DCs isolated from the organs of infected 
mice after in vitro re-stimulation with heat-killed S. aureus. DCs were puri-
fied from the spleen of S. aureus-infected mice at 24 h after bacterial inoculation 
and stimulated with 107 heat-killed S. aureus for 16 h. Release of IL-12 (A), TNF-
 (B) and IL-6 (C) in the culture supernatant were quantified by ELISA. Each bar 
represents the mean ± SD of triplicates from three independent experiments. ***, 
p < 0.001. 
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5.6 Reconstitution of DCs-depleted mice by adoptive transfer of   
   DCs reverses the effect of DC depletion in the course of  
   S. aureus infection 
Van Rijt et al. reported that treatment of CD11c-DTR mice with DT also 
induces the depletion of alveolar macrophages since this cell population 
expresses high levels of CD11c [111]. Therefore, the effect of DT treat-
ment in the alveolar macrophage population of CD11c-DTR mice was in-
vestigated. CD11c and CD11b markers were used to differentiate  
alveolar macrophages (CD11chigh/CD11blow) from lung DCs 
(CD11cintermediate/CD11bhigh). The results show that treatment with DT in-
Figure 13: Depletion of DCs aggravates the severity of S. aureus infec-
tion. (A) Survival curves of DCs-depleted (broken line) and non-depleted 
(continuous line) mice after intravenous inoculation with S. aureus. Bacteri-
al loads (B) and pathology scores (C) in the organs of DCs-depleted (black 
bars) and non-depleted (white bars) mice at 24 h after bacterial inoculation. 
(D) Bacterial loads in the organs of DT-treated (black bars) or PBS-treated 
(white bars) BALB/c mice at 24 h after S. aureus inoculation. Data are rep-
resentative of three independent experiments. **, p < 0.01; ***, p < 0.001. 
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duced extensive depletion of alveolar macrophages (Figure 14B, Gate 1) 
in addition to the depletion of lung DCs (Figure 14B, Gate 2), 
 
 
 
 
 
  
 
 
 
To determine whether the loss of DCs, but not of alveolar macrophages 
was directly responsible for the exacerbation of infection, CD11c-DTR 
mice were adoptively transferred with DCs obtained from normal BALB/c 
mice. The capacity of adoptively transferred matured or immature DCs to 
migrate into the spleen (Figure 15A) and lungs (Figure 15B) was con-
firmed by flow cytometry analysis using CFSE-labeled DCs. As shown in 
Figure 16, reconstitution with DCs returned the capacity of CD11c-DTR 
mice to control the infection in the lungs and kidneys. 
 
 
 
Figure 14: Depletion of alveolar macrophages in CD11c-DTR mice after 
treatment with DT. Flow cytometry analysis of lung cells from CD11c-DTR 
transgenic mice treated with either PBS (A) or with DT (B) and infected intrave-
nously with S. aureus 24 h thereafter. Lung cell populations were analyzed 24 h 
after bacterial inoculation. A single-cell suspension was obtained after enzymatic 
digestion of lung tissue and alveolar macrophages (Gate 1), DCs (Gate 2) and 
PMNs (Gate 3) identified by their relative expression of CD11c and CD11b. 
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Figure 15: Tracing of adoptively transferred CFSE-labeled DCs by flow  
cytometry. S. aureus-infected mice were intravenously injected with either ma-
ture or immature CFSE-labeled DCs and single cells released from whole 
spleen (A) or lung (B) digestion were analyzed by flow cytometry. Each bar rep-
resents the mean ± SD percentage of CFSE-stained DCs.  
 
Figure 16: DC reconstitution improves the capacity of DCs-depleted 
CD11c-DTR mice to control S. aureus infection. Bacterial loads in the lungs, 
kidneys and livers of CD11c-DTR mice treated with DT 24 h prior inoculation with 
S. aureus and intravenously injected at 16 h of infection with 106 DCs obtained 
from BALB/c mice. CFU were determined in the different organs at 24 h after 
DCs transfer. Each bar represents the mean ± SD of three independent experi-
ments. *, p < 0.05; ***, p < 0.001. 
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5.7 Adoptive transfer of DCs improves the course of infection in 
   BALB/c mice 
As depletion of DCs resulted in disease exacerbation, it can be hypothe-
sized that increasing the amount of DCs could improve the course of infec-
tion in BALB/c mice and thus be used as a therapeutic intervention. To 
test this assumption, BALB/c mice were injected with 106 immature or 
LPS-matured DCs 16 h after bacterial inoculation and the bacterial loads 
were determined in the systemic organs 24 h after the injection of DCs. 
Results in Figure 17 show that both immature and mature DCs improved 
the capacity of BALB/c mice to control S. aureus in the lungs.  
 
 
 
 
 
 
 
 
5.8 DCs do not contribute to direct killing of S. aureus 
The next step was to investigate the molecular mechanisms underlying the 
beneficial effect afforded by DCs during experimental S. aureus infection. 
As DCs are phagocytic cells, the ability of DCs to contribute to direct killing 
of S. aureus was evaluated. For this purpose, DCs were infected with S. 
aureus at a MOI of 1:10 and the amount of intracellular bacteria deter-
mined at progressive times of infection. The results in Figure 18 show that 
S. aureus survived within the DCs.   
Figure 17: Effect of adoptive transfer of DCs on the capacity of BALB/c 
mice to control S. aureus infection. Bacterial loads in the lungs, kidneys, and 
livers of BALB/c mice intravenously injected at 16 h after bacterial inoculation 
with either 106 mature DCs (white bars), 106 immature DCs (hatched bars), or 
PBS (black bars). CFU were determined in the different organs at 24 h after DCs 
transfer. Each bar represents the mean ± SD of three independent experiments. 
***, p < 0.001. 
 
 
Results 
33 
 
 
 
 
 
 
 
 
 
 
Live-cell imaging analysis of infected DCs demonstrated that S. aureus 
was not only capable to survive but it was also capable to replicate within 
the DCs (Figure 19). 
 
  
  
 
 
Figure 18: S. aureus survives within DCs. DCs were infected with S. aureus 
and the number of viable intracellular bacteria was determined at progressive 
times of infection by lysing host cells, plating the lysates on agar plates, and 
counting the number of colonies. 
 
Figure 19: S. aureus replicates within the DC. Examples of real time movie 
(Video S2, see appendix I. Videos) images of a DC infected with GFP-expressing 
S. aureus in a photographic sequence lasting for approximately 1 h and 15 min. 
14:26:44 15:21:23 15:32:43 15:42:23 
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5.9 Depletion of DCs leads to an enhanced recruitment of PMNs  
   into the lungs of infected mice 
As a direct contribution of DCs to bacterial killing was excluded, the possi-
bility that the beneficial effect of DCs was due to their involvement in the 
recruitment of inflammatory cells involved in bacterial clearance was in-
vestigated. For this purpose the lungs were removed from DCs-depleted 
and non-depleted mice before and 24 h after S. aureus inoculation, di-
gested and the amount of PMNs was determined by flow cytometry analy-
sis. The results demonstrate an enhanced recruitment of PMNs into the 
lungs of DC-depleted animals, not only in percentage (Figure 14, Gate 3), 
but also in total numbers (Figure 20). 
 
   
 
 
 
 
 
 
 
Figure 20: DC-depletion is associated with an increased recruitment of 
PMNs in the lungs of S. aureus-infected mice. (A) Representative histograms 
for expression of Gr-1 molecule (PMNs) in the lung cells of uninfected (upper 
panel), S. aureus-infected and PBS-treated (middle panel) or S. aureus-infected 
and DT-treated (lower panel) CD11c-DTR mice at 24 h after bacterial inoculation. 
(B) Absolute number of PMNs recruited into the lungs in the above-mentioned 
groups. Each bar represents the mean ± SD of three independent experiments.  
*, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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5.10 PMNs recruited within the lungs of DC-depleted mice  
     harbor higher numbers of viable intracellular bacteria than   
     PMNs within the lungs of non-depleted mice 
Since several publications have reported that PMNs contribute to the 
clearance of S. aureus infections [62-64], higher numbers of PMNs should 
correlate with better bacterial clearance rather than with increased bacte-
rial loads. However, other studies have also reported that increased bacte-
rial burdens at the site of S. aureus infection correlated with excessive 
numbers of migrating PMNs harboring intracellular viable bacteria [112, 
113]. To determine if the PMNs infiltrating the lungs of S. aureus-infected 
mice harbored viable bacteria, PMNs were isolated out of the lungs of de-
pleted and non-depleted CD11c-DTR mice, treated with lysostaphin to 
eliminate extracellular bacteria and plated. The results in Figure 21A 
show, that significantly higher number (20-fold) of viable S. aureus cells 
were found in the PMN population isolated from the lungs of DC-depleted 
than from the lungs of non-depleted mice. More interestingly was the ob-
servation that the amount of viable S. aureus per PMN was also signifi-
cantly higher (10-fold) in the PMNs isolated from the lungs of DC-depleted 
than non-depleted mice (Figure 21B).  
 
 
 
 
 
Figure 21: Higher amount of viable S. aureus are present within the PMNs 
recruited into the lungs of DC-depleted than in those of non-depleted 
mice. Quantification of viable intracellular S. aureus in the total population of 
PMNs (A) or per 105 PMNs (B) in the lungs of S. aureus-infected DT-treated 
(black bars) or PBS-treated (white bars) CD11c-DTR mice at 24 h after bacte-
rial inoculation. Each bar represents the mean ± SD of three independent ex-
periments. *, p < 0.05. 
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5.11 Higher levels of CXC chemokines are produced in the  
     lungs of DC-depleted than in the lungs of non-depleted  
     S. aureus-infected mice  
Because CXC chemokines such as KC and MIP-2 have been reported not 
only to promote PMN migration but also the uptake of S. aureus into a 
compartment that permits its survival within PMNs [112], the levels of KC 
and MIP-2 in the lungs of S. aureus-infected mice in the presence and ab-
sence of DCs were determined. A significantly increased KC (Figure 22A) 
and MIP-2 (Figure 22B) concentration in the lungs of DC-depleted mice 
compared with non-depleted animals was observed.  
 
 
 
 
 
 
 
 
 
  
 
These findings suggest that DCs influence both the recruitment of PMNs 
into the tissue of S. aureus-infected mice as well as the antimicrobial ca-
pacity of these phagocytic cells via the regulation of lung KC and MIP-2 
production. 
 
Figure 22: Amount of CXC chemokines in the lungs of S. aureus-infected 
mice in the presence or absence of DCs. Whole-lung KC (A) and MIP-2 (B) 
levels in uninfected (white bars) and S. aureus-infected (black bars) either DT-
treated or PBS-treated CD11c-DTR mice at 24 h after bacterial inoculation. The 
levels of KC and MIP-2 were determined in lung homogenates by ELISA. Each 
bar represents the mean ± SD of three independent experiments. **, p < 0.01; ***, 
p < 0.001. 
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5.12 Partial depletion of PMNs does not reverse the detrimental  
    effect of DC depletion 
Gresham et al. [112] reported that partial depletion of PMNs in S. aureus-
infected mice resulted in lower amount of bacteria in organs and increased 
survival rate. To determine if partial depletion of PMNs can reduce the 
bacterial burdens in the experimental setting used in the study presented 
here, DCs-depleted mice were treated with 5 µg of anti-RB6 antibodies to 
achieve a partial depletion of circulating PMNs (30% of depletion) prior to 
intravenous infection with S. aureus. As shown in Figure 23, a partial de-
pletion of PMNs did not influence the bacterial loads in the organs of DC-
depleted mice determined at 24 h after bacterial inoculation. 
  
   
 
5.13 Influence of S. aureus in the capacity of DCs to stimulate  
    naïve antigen-specific CD4+ T cells 
DCs are potent antigen-presenting cells (APCs) that possess the ability to 
stimulate naïve T cells. To determine the influence of S. aureus in the ca-
pacity of DCs to stimulate naïve antigen-specific CD4+ T cells, DCs (either 
infected or uninfected) were loaded with OVA323-339 or left untreated and 
co-cultivated with CD4+ T cells from OT-II mice, which are specific for this 
peptide. A significantly higher proliferation was observed when CD4+ T 
Figure 23: Effect of partial depletion of PMNs on bacterial burdens in the 
organs of DC-depleted mice. Bacterial loads in the organs of DCs-depleted 
mice, which have been partially depleted of PMNs (black bars) or left untreated 
(white bars) at 24 h after intravenous inoculation with S. aureus. Each bar repre-
sents the mean ± SD of two independent experiments. 
Results 
 
38 
 
cells were co-cultivated with S. aureus-infected OVA-loaded DC in com-
parison to those co-cultivated with uninfected OVA-loaded DCs  
(Figure 24).  
 
   
 
 
 
 
Figure 24: Proliferation of naïve CD4+ T cells after co-cultivation with unin-
fected or S. aureus-infected OVA-loaded DCs. CD4+ T cells from OT-II trans-
genic mice were co-cultivated with uninfected or S. aureus-infected, OVA-loaded 
or unloaded DCs. The proliferative capacity of CD4+ T cells was measured by the 
incorporation of [methyl-3H]Thymidine. Each bar represents the mean cpm ± SD 
of triplicates. Result from one single experiment is shown. ***, p < 0.001. 
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6. Discussion 
During the last decades, an increasing number of infections caused by S. 
aureus has been reported worldwide [1, 2]. The increasing prevalence of 
staphylococcal infections is a direct consequence of the continuing evolu-
tion of antimicrobial resistance among S. aureus strains, added to the in-
creased use of implantable devices and the boosting in the number of pa-
tients with immunocompromised status because of HIV infection or immu-
nosuppression after transplantation or cancer treatment [114-116]. There-
fore, new therapeutic options with novel models of actions that may cir-
cumvent antibiotic resistance are required to tackle the problem posed by 
S. aureus in a more effective way. In this regard, therapeutic approaches 
aimed to enhance the efficiency of the host immune response to eliminate 
S. aureus may represent the best option. However, a more precise 
knowledge of the immune mechanisms involved in host defense against  
S. aureus is required in order to understand how the immune system can 
be manipulated to achieve a more efficient control of infection. 
In this work, the role of DCs, a subset of cells unique in their capacity to 
regulate the immune response, in the pathogenesis of S. aureus infections 
was investigated.  
First, the interactions between DCs and S. aureus were evaluated using 
live-cell imaging microscopy (see section 5.1). The results of these exper-
iments demonstrate the remarkable capacity of DCs to trace and phago-
cyte S. aureus. After encounter S. aureus, DCs initiated a maturation pro-
cess as shown by the up-regulation of co-stimulatory molecules CD40, 
CD80, CD86, and MHC class II as well as the release of proinflammatory 
cytokines IL-6, IL-12, and TNFα. 
A murine model of infection was used to investigate the behavior of DCs 
during S. aureus infection under in vivo conditions. In this model, BALB/c 
mice were intravenously infected with S. aureus strain SH1000 as previ-
ously described [64]. Examination of the amount of DCs in lungs and 
spleen of infected mice at progressing times after bacterial inoculation 
demonstrated that DCs were mobilized and actively recruited into infected 
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tissue during the course of infection. Isolation and in vitro re-stimulation of 
the recruited DCs with heat-killed S. aureus or with the TLR-9 ligand CpG 
revealed that these cells were in a more advance stage of activation than 
DCs from uninfected animals since they produced significantly higher lev-
els of inflammatory cytokines. 
The next step was to determine the relevance of DCs for host defense 
against S. aureus infection. For this purpose, CD11c-DTR transgenic 
mice, which allows for selective depletion of DCs [105], were used. Deple-
tion of DCs resulted in substantial worsening of pathogen clearance, par-
ticularly in the lungs and kidneys, and in accelerated mortality of infected 
animals. In accordance with this data, a recent study reported that deple-
tion of DCs in mice intranasally inoculated with S. aureus was associated 
with an increased bacterial load in the lungs [117]. To exclude an influence 
of the DT itself on the course of S. aureus infection, BALB/c mice were 
treated with DT before infection in a similar way as CD11c-DTR mice were 
treated and bacterial loads were monitored. Treatment with DT alone had 
no effect on the course of infection confirming that the observed exacerba-
tion of infection was indeed caused by DC depletion and not by side ef-
fects of DT treatment.  
As the lung was the most affected organ by DC depletion and it has been 
shown that alveolar macrophages can also be depleted by DT treatment 
[111], the potential depletion of alveolar macrophages by DT treatment in 
the experimental settings used in this study was evaluated. The CD11c 
and CD11b markers were used to differentiate alveolar macrophages 
(CD11chigh/CD11blow) from lung DCs (CD11cintermediate/CD11bhigh) by FACS 
analysis. The results show that, in addition to the depletion of lung DCs, 
treatment with DT induced extensive depletion of alveolar macrophages 
(Figure 14). To determine whether the loss of DCs but not of alveolar mac-
rophages was directly responsible for the exacerbation of infection, DC-
depleted CD11c-DTR mice were adoptively transferred with bone marrow-
derived DCs obtained from BALB/c mice. The obtained results demon-
strated that intravenous injection of DCs returned the capacity of DCs-
depleted CD11c-DTR mice to control the infection to the levels observed 
Discussion 
41 
 
in non-depleted animals clearly confirming that the observed increased 
severity of infection in DT-treated CD11c-DTR mice was specifically at-
tributable to the reduction of DCs (Figure 16). 
As the above-presented data indicates that DCs played an important role 
in host defense against S. aureus infection, it was then hypothesized that 
increasing DC numbers in normal BALB/c mice could improve their re-
sistance to S. aureus infection. Indeed, adoptive transfer of either imma-
ture or LPS-matured DCs into normal BALB/ mice improved the capacity 
of these animals to clear S. aureus in the lungs (Figure 17). These results 
implied that DCs do not only play a protective role during S. aureus infec-
tion but may also be used as a therapeutic intervention. 
The next step was to investigate the immunological mechanisms underly-
ing the beneficial effect afforded by DCs during S. aureus bloodstream 
infection. As DCs are phagocytic cells, the ability of DCs to contribute to 
direct killing of S. aureus was evaluated. For this purpose, DCs were in-
fected with S. aureus and the amount of intracellular bacteria was moni-
tored at progressive times of infection. Interestingly, the DCs were not ca-
pable to kill the intracellular S. aureus, as the number of viable bacteria 
remained unaltered over time. Furthermore, live-imaging microscopy 
demonstrated the ability of S. aureus to replicate within the infected DCs 
(Video S2). Likewise, S. aureus has been shown to survive within other 
professional phagocytes, such as human [118] and murine PMNs [112] as 
well as human monocyte-derived macrophages [119]. Within these cells, 
S. aureus can evade the lethal effect of the phagolysosome by producing 
oxygen free radicals scavenger compounds such as catalases [120], 
staphyloxanthin [121], and yellow carotenoid pigments [12].  
After the demonstration that DCs do not play a major role in direct bacteri-
al clearance, it was then hypothesized that DCs may indirectly contribute 
to bacterial killing through their participation in the recruitment of inflamma-
tory cells involved in bacterial eradication into the site of infection. As it 
has long been known that PMNs play a key role in the host innate immune 
response towards S. aureus [62-64], the amount of PMNs recruited in the 
lungs of DC-depleted and non-depleted mice during the course of S. 
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aureus infection was monitored. The obtained results revealed that the 
recruitment of PMNs in infected tissue was increased rather than de-
creased in mice depleted of DCs (Figure 20). These findings demonstrate 
that exacerbation of S. aureus infection in DC-depleted mice was not at-
tributable to a reduced recruitment of PMNs and also suggest that increas-
ing the number of PMNs in infected organs was rather detrimental to the 
host. Despite their role in bacterial clearance, there is now substantial evi-
dence suggesting that through the release of cytotoxic compounds PMNs 
themselves can contribute to the pathogenesis of tissue injury associated 
with staphylococcal infection [122]. Furthermore, the results also indicate 
that the increase neutrophil numbers in DC-depleted mice correlate with 
increase in bacterial counts rather than with increased bacterial killing. 
Similar observations have been reported in murine models of S. aureus 
peritonitis [112] and hind paw infection [113] as well as in patients with S. 
aureus bloodstream infections [123-125]. 
Even more interestingly was the observation that neutrophils isolated from 
the lungs of DC-depleted mice harbored significantly higher numbers of 
intracellular viable S. aureus than those isolated from non-depleted ani-
mals (Figure 21). This implies that the ability of the recruited neutrophils to 
kill ingested S. aureus is even poorer in the absence of DCs. In this re-
gard, several studies have provided evidence that local release of CXC 
chemokines promoted survival of S. aureus within neutrophils by facilitat-
ing bacterial internalization into an intracellular niche where they are pro-
tected from the host’s killing mechanisms [112, 113]. In accordance with 
those studies, it was found that the levels of KC and MIP-2 in the lungs of 
DC-depleted S. aureus-infected mice were significantly higher than in non-
depleted animals. Therefore, it is likely that DCs can regulate the produc-
tion of CXC chemokine by other cell populations such as epithelial cells in 
the infected tissue. 
In summary, the results of this study provide compelling evidence that 
DCs are important for host defense against S. aureus infection. It can be 
proposed that by orchestrating the local production of CXC chemokine and 
the recruitment and functional activity of PMNs DCs serve as modulators 
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of the local inflammatory responses elicited during S. aureus infection to 
prevent tissue injury.  
DCs are also very important players during the development of an adap-
tive immune response [44]. CD4+ T cells respond to peptide antigen dis-
played on MHC class II expressed on the surface of dendritic cells. Acces-
sory molecules such as CD80 and CD86 expressed by DCs are required 
to ensure that T cells will divide and differentiate into effector cells. As DCs 
were capable to up-regulate the expression of MHC class II and accessory 
molecules in response to S. aureus infection, the capacity of infected DCs 
to stimulate naïve antigen-specific CD4+ T cells was examined using OT-II 
transgenic mice. The results show that OVA-loaded S. aureus-infected 
DCs induced significantly higher levels of proliferation in CD4+ T cells from 
OT-II mice than OVA-loaded uninfected DCs. These results indicate that 
DCs may also play an important role driving the generation of the primary 
antigen-specific immune response during S. aureus infection. More de-
tailed analysis of the role of DCs on the acquired immune response to S. 
aureus should be performed in future studies.  
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Appendix 
A. Antibiotics and chemicals 
[methyl-3H]Thymidine Amersham, Buchler, Germany 
3,3´,5,5´-Tetramethylbenzidine 
(TMB) 
Sigma Aldrich, Steinheim, Germany 
Agarose Sigma Aldrich, Steinheim, Germany 
Ammonium chloride (NH4Cl) Roth, Karlsruhe, Germany 
Aprotinin Sigma Aldrich, Steinheim, Germany 
Bovine Serum Albumin fraction V 
(BSA) 
Applichem, Darmstadt, Germany 
Carboxyfluorescein succinimidyl 
ester (CFSE) 
eBiosciences, Frankfurt, Germany 
Chloramphenicol Sigma Aldrich, Steinheim, Germany 
D-Glucose Applichem, Darmstadt, Germany 
Disodium hydrogen phosphate  
dihydrate (Na2HPO4·2H2O) 
Roth, Karlsruhe, Germany 
DNase I Quiagen, Hilden, Germany 
Ethanol (96%) J.T. Baker, Griesheim, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma Aldrich, Steinheim, Germany 
Fetal calf serum Biochrom, Berlin, Germany 
Gentamicin Sigma Aldrich, Steinheim, Germany 
Glycerol Sigma Aldrich, Steinheim, Germany 
Hydrochloric acid (HCL), 37% J.T. Baker, Griesheim, Germany 
Leupeptine Merck, Darmstadt, Germany 
Lysozyme Sigma Aldrich, Steinheim, Germany 
Ova323-339 peptide Genscript, Piscataway, NJ, USA 
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Phenylmethyl sulfonyl fluoride 
(PMSF) 
Merck, Darmstadt, Germany 
Polyoxyethylene Sorbitan 
Monolaurate (Tween-20) 
Sigma Aldrich, Steinheim, Germany 
Potassium bicarbonate (KHCO3) Roth, Karlsruhe, Germany 
Potassium chloride (KCl)  Roth, Karlsruhe, Germany 
Potassium dihydrogen phosphate 
(KH2PO4) 
Roth, Karlsruhe, Germany 
Potassium dihydrogen phosphate 
(KH2PO4) 
Roth, Karlsruhe, Germany 
Proteinase K Merck, Darmstadt, Germany 
RPMI 1620 Gibco-Invitrogen, Darmstadt,  
Germany 
Sodium carbonate (Na2CO3) Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) Roth, Karlsruhe, Germany 
Sodium hydroxide (NaOH) Sigma Aldrich, Steinheim, Germany 
Sulfuric acid (H2SO4) Roth, Karlsruhe, Germany 
Trizma Base Sigma Aldrich, Steinheim, Germany 
 
B. Buffer 
0.05% Tween/PBS (5 l) 250 ml 20x PBS 
2.5 ml Tween 20 
ad 5 l Aq. dest. 
1 M HCl (100 ml) 8.4 ml 37% HCl 
ad 100 ml Aq. dest. 
1 M NaOH (500 ml) 20 g NaOH, ad 500 ml Aq. dest. 
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1x PBS, pH 7.4 (1 l) 50 ml 20x PBS, pH 7.4 
ad 1 l Aq. dest., autoclave 
20x PBS, pH 7.4 (5 l) 800 g NaCl 
20 g KCl 
144 g Na2HPO4·2H2O 
24 g KH2PO4 
ad 5 l Aq. dest.  
adjust pH 7.4 with NaOH  
5 mM Tris, pH 8.8 (100 ml) 0.0606 g Trizma Base,  
ad 100 ml Aq. dest.  
adjust pH 8.8 with HCl 
Ammonium-Chloride-Potassium 
buffer (ACK) 
0.01 M KHCO3 
0.155 M NH4Cl 
0.1 mM EDTA 
 ad 1 l Aq. dest. 
adjust pH 7.4 with HCl 
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Lysis buffer, pH 7.4 (1 l) 200 mM NaCl 
5 mM ethylenediaminetetraacetic 
acid 
10 mM Tris 
10% glycerol 
1 mM phenylmethyl sulfonyl fluoride 
1 µg/ml leupeptine 
28 µg/ml aprotinin 
ad 1 l Aq. dest. 
adjust pH 7.4 with NaOH,  
store at -20 °C 
 
C. Expendable materials and Instruments 
Blood agar plates Invitrogen, Darmstadt, Germany 
Cell culture plates Invitrogen, Darmstadt, Germany 
Cell harvester Inotech, Wohlen, Switzerland 
Cell nylon meshes BD Bioscience, NY, USA 
Centrifuge Tubes Greiner Bio One, Frickenhausen, 
Germany 
ELISA Reader Tecan Group Ltd, Männedorf,  
Switzerland 
FACSCalibur™ flow cytometer  BD Biosciences, CA, USA 
Filtermats A 1450-421 Perkin Elmer/ Wallac, Freiburg, 
Germany 
 
Heraeus Biofuge  Thermo Electron, Bremen,  
Germany 
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Manual MACS Separators Miltenyi Biotec, Bergisch Gladbach, 
Germany 
MeltiLex solid scintillator Perkin Elmer/ Wallac, Freiburg, 
Germany 
MicroBeta cassette Perkin Elmer/ Wallac, Freiburg, 
Germany 
Microcentrifuge tubes Eppendorf, Hamburg, Germany 
MS columns Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Needles Braun, Melsungen, Germany 
Pipetboy IBS Integra Bioscience, Fernwald, 
Germany 
Pipette, 5ml and 10ml Greiner Bio One, Frickenhausen, 
Germany 
Syringes Braun, Melsungen, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Tissue homogenizer Biolab, Gödenstorf, Germany 
Vortex-Genie2 Scientific Industries, NY, USA 
Wallac MicroBeta® TriLux Perkin Elmer/ Wallac, Freiburg, 
Germany 
 
D. Media for bacteria culture 
Brain heart infusion (BHI) Sigma Aldrich, Steinheim, Germany 
37g BHI culture media, ad 1 l Aq. 
dest., autoclave 
 
Appendix 
61 
 
E. Media and supplements for cell culture 
Fetal calf serum (500 ml) Adjust 500 ml FCS to 37 °C ,heat-
inactivate for 30 min at 56 °C,  
store at -20 °C 
L-Glutamine (200 mM) PAA Laboratories, Pasching,  
Austria 
Penicillin/Streptomycin, 100x PAA Laboratories, Pasching,  
Austria 
Recombinant murine GM-CSF eBiosciences, Frankfurt, Germany 
Recombinant murine IL-4 eBiosciences, Frankfurt, Germany 
RPMI complete medium (500 ml) RPMI 1620, add  
10% FCS 
100 U/ml Penicillin 
50 mg/ml Streptavidin 
1 mM L-Glutamine  
0.5 µM 2-mercaptoethanol 
 
F. Antibodies 
Anti-CD11c magnetic beads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
Anti-CD40 Invitrogen, Darmstadt, Germany 
Anti-CD4-PE BD Bioscience, NY, USA 
Anti-CD80 Invitrogen, Darmstadt, Germany 
Anti-CD86 Invitrogen, Darmstadt, Germany 
Anti-MHC class II Invitrogen, Darmstadt, Germany 
Anti-PE magnetic beads Miltenyi Biotec, Bergisch Gladbach, 
Germany 
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Anti-RB6 Kind gift from Dr. Siegfried Weiß, 
HZI 
BD OptEIATM Mouse ELISA kit 
(IL-6, IL-12, TNF-α) 
eBiosciences, Frankfurt, Germany 
KC and MIP ELISA kit R&D Systems, Minneapolis, USA 
                                                                                             
G. Mice 
B6.FVB-Tg [Itgax-DTR/GFP] 
57Lan/J transgenic mice (CD11c-
DTR) 
Kind gift from Steffen Jung,  
The Weizmann Institute of Science,  
Rehovot, Israel 
BALB/c Harlan-Winkelmann, Borchen,  
Germany 
Ovalbumin specific mice B6.Cg-
Tg(TcraTcrb)425Cbn/J (OT-II) 
Jackson Laboratory, Maine, USA 
 
H. Abbreviations 
°C degree Celsius 
µg Microgram 
BHI Brain-heart infusion 
CD cluster of differentiation 
CFSE carboxyfluorescein succinimidyl 
ester 
CFU colony forming units 
DC dendritic cell 
dH2O distilled water 
DT diphtheria toxin 
EDTA ethylenediaminetetraacetic acid 
ELISA Enzyme-Linked Immunosorbent 
Assay 
FCS fetal calf serum 
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FnBPA fibronectin binding protein 
GFP green fluorescencent protein 
h Hour 
H&E hematoxylin and eosin 
i.p. Intraperitoneal 
i.v. Intravenous 
LPS lipopolysaccaride 
MHC major histocompatibility complex 
min Minute 
ml Milliliter 
mM milli molar 
MOI multiplicity of infection 
 
MRSA Methicillin-resistant Staphylococcus 
aureus 
MSCRAMMs microbial surface components  
recognizing adhesive matrix mole-
cules 
NADPH nicotinamide adenine dinucleotide 
phosphate 
nm Nanometer 
PBS phosphate buffered saline 
pH potentia Hydrogenii 
PMN polymorphonuclear PMNs 
Rpm rotates per minute 
S. aureus Staphylococcus aureus 
SD standard deviation 
TCR T cell receptor 
TMB 3,3',5,5'-Tetramethyl benzidine 
TSST-1 toxic shock syndrome toxin 1 
VRSA Vancomycin-resistant Staphylococ-
cus aureus 
YOPs Yersinia outer proteins 
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I. Videos 
The Videos S1 (Phagocytic uptake of S. aureus by DCs) and S2  
(S. aureus replicates within the DC) are available as avi files. Printed cop-
ies of this dissertation comprise the videos on the enclosed CD-R. 
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